Short answer
Hims & Hers Health, Inc. (HIMS) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $753M (up 38.2% year over year) with net income of −$86M.
Q2 2026 key financials · XBRL
- Revenue
- $753M
- +38.2% YoY · +23.9% QoQ
- Net income
- −$86M
- −303.0% YoY · +6.3% QoQ
- Operating margin
- -12.9%
- Gross margin
- 63.8%
- EPS (diluted)
- −$0.38
- −323.5% YoY · +5.0% QoQ
Source: XBRL data from the Hims & Hers Health, Inc. (HIMS) Q2 2026 10-Q on SEC EDGAR. USD.
Hims & Hers Health, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $753.2M, up 38% YoY from $544.8M, driven by Rest of World revenue up 1,641% to $131.4M
- Net loss $86.3M, net margin (11)% vs 8% YoY; Adjusted EBITDA margin 8% vs 15%
- Best-performing line Hers brand, over 40% of U.S. revenue vs approximately 35% YoY
- Subscribers 2.9M, up 19% YoY; monthly revenue per average subscriber $92 vs $76
- Near-term headwinds: shorter shipping cadences pressuring gross margins and investments expected to increase operating expenses
Risk Factors
- Compounded GLP-1 enforcement risk triggered by February 2026 FDA restrictions and HHS referral to DOJ
- Weight-loss transition risk from March 2026 shift toward branded GLP-1 medications and limited compounded access
- Regulatory advertising risk from influencer promotion of prescription medicines, prohibited in the United Kingdom, European Union, and Canada
- Near-term demand risk as compounded-treatment customers may resist branded therapies, reducing conversion and increasing churn
- Margin risk from branded GLP-1 procurement costs and limited ability to pass through price increases
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Hims & Hers Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.